Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.59 |
| ▸ | DRD4 | P21917 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2793001 | 1.00 | ADRB2 (0.66) | ADRB2ADRB1ADRA1DDRD2DRD1 | |
| SCHEMBL13170745 | 1.00 | ADRB2 (0.66) | ADRB2ADRB1ADRA1DDRD2DRD1 | |
| Formic Acid SCHEMBL4340904 | 0.98 | ADRB2 (0.63) | ADRB2ADRB1ADRA1DDRD2DRD1 | |
| Formic Acid SCHEMBL4340907 | 0.98 | ADRB2 (0.63) | ADRB2ADRB1ADRA1DDRD2DRD1 | |
| SCHEMBL524584 | 0.91 | ADRB2 (0.69) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL2794542 | 0.91 | ADRB2 (0.69) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL2797776 | 0.90 | ADRB2 (0.53) | ADRB2ADRB1ADRA1DDRD2DRD1 | |
| SCHEMBL13170245 | 0.88 | ADRB2 (0.64) | ADRB2ADRB1ADRA1DDRD2DRD1 | |
| Succinic Acid SCHEMBL15299950 | 0.88 | ADRB2 (0.64) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL2798103 | 0.88 | ADRB2 (0.64) | ADRB2ADRB1ADRA1DDRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210643-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. | 2015-07-30 | — | — | US | claimed |
| EP-2057122-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2010-09-01 | — | — | EP | claimed |
| US-20100168161-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-07-01 | — | — | US | claimed |
| US-20150210643-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. | 2015-07-30 | — | — | US | disclosed |
| EP-2057122-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2010-09-01 | — | — | EP | disclosed |
| US-20100168161-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168161-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885ADRA1D 7/4885 |
| US-20150210643-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885ADRA1D 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.